- Видео 184
- Просмотров 1 332
Retina Today
США
Добавлен 8 мар 2024
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Or...
We’ve got to keep our eye on the pipeline. What do the latest data tell us about two drug candidates? Durga Borkar, MD, MMCi, reviews data from a phase 2 study assessing the safety and efficacy ONL1204 (ONL Therapeutics) delivered prior to RRD surgery. Did injecting ONL1204, which prevents Fas activation, lead to any postsurgical differences? Alex Melamud stops by to discuss the phase 2/3 SAGA study assessing the safety and efficacy of gildeuretinol (Alkeus Pharmaceuticals), an oral agent for the treatment of geographic atrophy. Can this drug succeed where other oral options in retina have failed?
Просмотров: 5
Видео
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMD
Просмотров 1521 час назад
The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study’s findings, and preview the next phases of the trial. And Eric Schneider, MD, joins the...
AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining Reimbursement
Просмотров 1914 дней назад
Are retina doctors seeing more retinal pathology following infection or vaccination? Or is there nothing to see here? Rahul Khurana, MD, joins us to discuss the findings of various health care database analyses seeking to clarify whether COVID infection or vaccination were linked to retinal manifestations. Was there a clear-or even an opaque-connection between the two? And Paul Hahn, MD, PhD, s...
GA Options in Clinical Therapy: Why Aren't Doctors Embracing Complement Inhibition?
Просмотров 1414 дней назад
We finally have two FDA-approved treatments for geographic atrophy (GA)-and yet, many retina specialists have been reluctant to embrace them. Join moderator John Kitchens, MD, as he explores this question with Miguel Busquets, MD, and Esther Kim, MD. Further in the episode, they gameplan patient conversations centered around choosing a treatment, ask how heavily to weigh safety when selecting a...
New Retina Radio Journal Club with VBS: Pre-treatment with Chlorhexidine vs. Povidone-Iodine in E...
Просмотров 728 дней назад
In this episode of the New Retina Radio Journal Club with VBS, Maura Di Nicola, MD; Sruthi Arepalli, MD, and Barton Blackorby, MD, discuss a recent study comparing endophthalmitis rates following anti-VEGF injections with pre-treatment using either 5% Povidone Iodine or 0.05% Chlorhexidine. They highlight how prefilled syringes can reduce the risk of endophthalmitis and explore the implications...
Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet ...
Просмотров 18Месяц назад
Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress-and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about ...
New Retina Radio Journal Club w/ VBS: Risk of Death, Stroke, and MI After RAO
Просмотров 10Месяц назад
What is the relationship between retinal artery occlusion (RAO) and death, stroke, or myocardial infarction? Moderator Katherine Talcott, MD, is joined by Kyle Kovacs, MD, and Phoebe Mellen, MD, to explore the latest contribution to the literature on this topic. After the break, they discuss how best to manage patients who present to the clinic with an RAO, review academic centers' model for ra...
ASRS ’24: C1q Inhibition and Metformin for AMD
Просмотров 232 месяца назад
Could inhibition of C1q effectively halt the progression of GA? Joel Pearlman, MD, PhD, sat down to discuss findings from the phase 2 ARCHER study, which evaluated ANX007 (Annexon) in patients with GA. He tells us what happened when patients were dosed with ANX007 for 1 year-and what occurred when patients stopped receiving treatment. And later, Dimitra Skondra, MD, fills us in on the latest re...
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History...
Просмотров 212 месяца назад
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinic...
ASRS ’24: PAVILION at 100 Weeks
Просмотров 142 месяца назад
The Port Delivery System with Ranibizumab (PDS; Susvimo, Genentech) was shown to be effective for wet AMD treatment. What did the PAVILION study find when it came to treating diabetic retinopathy out to 100 weeks? Margaret Chang, MD, summarized the PAVILION study’s 2-year safety and efficacy findings regarding the PDS in patients with DR but no DME. Plus, Dr. Chang offers her opinions on what i...
ASRS ’24: ACP in Patients with Major EZ Attenuation, and GALE Microperimetry Findings
Просмотров 693 месяца назад
Is avacincaptad pegol (Izervay, Astellas) effective in patients with major ellipsoid zone attenuation at baseline? Katherine Talcott, MD, stopped by our studio in Stockholm during ASRS with a top-line summary of her lecture at this year’s meeting. And Sunir Garg, MD, joined us for a conversation about the GALE study, which assessed 36 months of continuous dosing of pegcetacoplan (Syfovre, Apell...
New Retina Radio Journal Club w/ VBS: Risk Factors for Switching from Bevacizumab to Aflibercept ...
Просмотров 143 месяца назад
Patients with DME in DRCR Retina Network Protocol AC were switched from bevacizumab to aflibercept if they met specific switch criteria. Where there any baseline factors that predicted a switch? Moderator Rebecca Soares, MD, sits down with panelists Matt Starr, MD, and Nikisha Kothari, MD, to review this study, ask whether the findings are clinically relevant, and explore other risk factors tha...
From Trials to the Clinic: Using a Therapy With a Novel MOA to Treat Patients With DME
Просмотров 214 месяца назад
One of the challenges associated with current anti-VEGF therapies for the management of DME is the need for frequent injections and the potential impact on adherence and vision outcomes. Join Dr. John Kitchens and Dr. Maria Berrocal as they share their experiences treating their DME patients using a therapy with a novel mechanism of action, and how those patient outcomes have influenced their e...
New Retina Radio Journal Club w/ VBS: RVOs During the COVID Pandemic
Просмотров 104 месяца назад
What did a review of the AAO IRIS Registry reveal about the rates of retinal vein occlusion (RVO) during the COVID-19 pandemic? Moderator Katherine Talcott, MD, sits down with Phoebe Mellen, MD, and Kyle Kovacs, MD, to review the study's conclusion that RVO rates did not increase during the pandemic, discuss challenges about talking to patients seeking causality for an ocular phenomenon, and re...
A Treatment With a Novel MOA for Patients With nAMD and DME: Perspectives From the Real World
Просмотров 134 месяца назад
Recent studies have proven the therapeutic viability of a different approach in treating retinal vascular diseases. Join Dr. John Kitchens, Dr. Margaret Chang, and Dr. David Chin Yee as they discuss their clinical experiences using a therapy with a novel mechanism of action in patients with nAMD and DME. And, learn how they approach managing patients with macular edema. This special episode of ...
AMD and DME Applications in the Retina Practice: Real-world Data
Просмотров 174 месяца назад
AMD and DME Applications in the Retina Practice: Real-world Data
ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depres...
Просмотров 125 месяцев назад
ARVO 2024 Coverage: UWF Leakage in Protocol AA, Machine Learning, and GA's Link to Anxiety/Depres...
New Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effec...
Просмотров 115 месяцев назад
New Retina Radio Journal Club with VBS: New Retina Radio Journal Club with VBS: Is Buckling Effec...
ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE
Просмотров 385 месяцев назад
ARVO 2024 Coverage: ≥20-week Dosing in PULSAR and TENAYA/LUCERNE
GA Options in Clinical Therapy, Part 2: Real-world Cases in GA
Просмотров 66 месяцев назад
GA Options in Clinical Therapy, Part 2: Real-world Cases in GA
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies
Просмотров 76 месяцев назад
GA Options in Clinical Therapy, Part 1: Patient Selection and Treatment Strategies
AMD and DME Applications in the Retina Practice: RCT Comparison
Просмотров 216 месяцев назад
AMD and DME Applications in the Retina Practice: RCT Comparison
The State of Biosimilars: Integration of Biosimilars into a Retina Practice
Просмотров 166 месяцев назад
The State of Biosimilars: Integration of Biosimilars into a Retina Practice
New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT
Просмотров 146 месяцев назад
New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT
Successful Management of Vitreous Opacities
Просмотров 187 месяцев назад
Successful Management of Vitreous Opacities
New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to...
Просмотров 57 месяцев назад
New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to...
Treating Geographic Atrophy (GA) In Your Practice
Просмотров 67 месяцев назад
Treating Geographic Atrophy (GA) In Your Practice
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
Просмотров 57 месяцев назад
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
The State of Biosimilars: How We Got Here and What It Means for Practice
Просмотров 127 месяцев назад
The State of Biosimilars: How We Got Here and What It Means for Practice